With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT), tumor recurrence remains the main limiting factor for long-term survival. Although sorafenib is available for advanced HCC, there is still a lack of data on the use of sorafenib for treatment of recurrent HCC after LT. Here, we report on four cases of the use of sorafenib for treatment of recurrent HCC after LT. The median time of recurrence from LT was 4 months (range, 1-16 months). Two of the four evaluated patients showed stable disease, which was the best response and the duration of stabilization was 11 months and 5 months, respectively. One patient also experienced stable disease and remained in stable disease without sorafenib therapy for 29 months and the total duration of stabilization was 38 months. The remaining patient showed partial response but stopped treatment due to radiological tumor progression during treatment. Although all cases were high risk group for recurrence such as above Milan criteria, vascular invasion and tumor biology, clinical outcomes showed some good results. Therefore, sorafenib may be an acceptable treatment option for recurrent HCC after LT. (Korean J Gastroenterol 2015;65:246-251) 
INTRODUCTION
The worldwide incidence of hepatocellular carcinoma (HCC) is rising and is actually estimated as 750,000 new patients per year. 1 Liver transplantation (LT) offers a potential cure by complete elimination of the tumor and underlying liver cirrhosis which will develop HCC. Although recurrence of HCC after LT has decreased significantly since using the Milan criteria, 8-12% of patients will develop HCC recurrence and will have a significantly diminished overall survival. The majority of patients with HCC recurrence after LT have multifocal or extrahepatic metastases; therefore, they are less likely to be candidates for loco-regional therapy such as resection, radiofrequency ablation, or transarterial chemoembolization (TACE). Therefore, palliative or systemic therapy is often the only treatment option in these patients.
Sorafenib is a multi-tyrosine kinase and angiogenesis inhibitor and randomized phase 3 trials have shown an overall 
CASE REPORTS
A summary of patient demographics, clinical characteristics and outcomes of the four patients is shown in Tables 1 and 2. 
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Case 2
A 57-year old woman was followed up for HBV-associated (Fig. 1E, F) . PET-CT also showed a hypermetabolic nodule (SUVmax 3.4) on RLL (Fig. 1G) . Based on the diagnosis of HCC metastasis to the lung, we performed wedge resection for metastatic RLL lesion in October 2012 and pathology also revealed metastatic HCC. After surgery, we started therapy with sorafenib at a dose of 400 mg twice daily in December 2012
for palliative therapy and one month later, dose adjustment (400 mg once daily) was required due to diarrhea. Her symptoms improved after dose adjustment and she was able to maintain sorafenib administration with a full dose of 400 mg twice daily. Further routine chest CT showed no interval change of a 3 mm sized lung nodule in the left upper lobe (Fig.   1H ). Total duration of treatment was 19 months and she is still alive for 21 months after recurrence.
Case 3
A 58-year old man was followed up for HBV-associated liver Fig. 2A, B) . Based on the diagnosis of HCC metastasis to the lung, we started therapy with sorafenib at a dose of 400 mg twice daily in July 2012. Five months after sorafenib administration, a chest CT showed that several variable sized multiple nodules on both lungs had decreased and some nodules remained (Fig. 2C, D) .
Further routine chest CT showed an interval increase in size of multiple lung nodules, which we considered as progressive disease. Total duration of treatment was 5 months and he is still alive for 23 months after recurrence.
Case 4
A 51-year old man was followed up for alcohol-associated After DDLT, he was routinely followed up and one month later, routine tumor marker levels such as AFP and PIVKA-II were increased and abdominal CT showed an enhancing mass (4.0×2.9 cm) at the right acetabulum (Fig. 2E) . Bone scan and PET-CT also showed bone metastasis in the right pelvic bone and the right third rib (Fig. 2G, H) . Based on the diagnosis of HCC metastasis to the bone, we started combination therapy with sorafenib at a dose of 400 mg twice daily and radiotherapy. Three weeks later, dose adjustment (400 mg once daily) was required due to grade 3 hand-foot skin reaction. Three months after sorafenib administration, an abdomen CT showed an interval decrease in the size of metastasis at the right acetabulum (Fig. 2H) . However, because further abdominal CT revealed new HCC at the liver, sorafenib administration was stopped. Unfortunately, despite receiving TACE for new HCC at the liver, he died due to poor general condition after TACE. Total duration of treatment was 12 months and overall survival was 14 months.
DISCUSSION
LT provides the optimal treatment for selected cirrhotic patients and HCC achieving a 5-year patient survival of ＞70%
and a HCC recurrence rate at 5 years of ＜15%. 4 Due to the scarcity of donor livers, expansion of the Milan criteria is continuously discussed. Although selected patients with larger tumors may achieve similar survival rates after LT as patients who are fulfilling expansion criteria of the Milan, 5-9 recurrence rate is significantly higher. and immunosuppression with an mammalian target of rapamycin (mTOR) inhibitor was applied in the majority of cases (79%). [13] [14] [15] [16] [17] Also, several recent studies reported that overall survival was significantly greater in patients on sorafenib compared with patients not on sorafenib. [18] [19] [20] The overall efficacy of sorafenib in our cases seems similar those of the above mentioned studies and does not seem inferior to that reported in the Asia-pacific trial, of which median time to progression and overall survival were 2.8 months and 6.5 months. 3 We found that all patients experienced adverse effects and grade 3 toxicity occurred in two patients. One patient experienced grade 3 diarrhea and the other patient grade 3 hand-foot skin reaction, but all symptoms were manageable with dose interruption and adjustment. Thus, there seems to be no clinically significant toxicity to administration of sorafenib.
According to RECIST guidelines, complete response means disappearance of all lesions and is very rare. Although there was no complete response in our cases, three of four cases showed some good results in spite of high risk group for recurrence such as above Milan criteria, vascular invasion and tumor biology; in particular, case 1 remains in stable disease without sorafenib therapy and is still alive for 38 months after recurrence. Recently, several centers have reported their retrospective experience with sorafenib, in most cases in combination with an mTOR-based immunosuppression. [13] [14] [15] [16] [17] Because of the heterogeneity of immunosuppression regimens, especially combination of mTOR inhibitor, these studies often limit interpretation of sorafenib efficacy. Thus, in our case, we experienced efficacy of sorafenib on recurrent HCC after LT.
Therefore, with careful monitoring, sorafenib may be used safely for recurrent HCC after LT. However, large prospective trials are required to determine the efficacy and safety of sorafenib for treatment of recurrent HCC after LT.
